Milestone rises after late-stage data from Chinese partner on heart rhythm drug

Milestone Pharmaceuticals

06/09/2024 13:12

** Shares of drug developer Milestone Pharmaceuticals
 MIST.O  rise 3.4% to $1.51 premarket  
    ** Co says its partner Ji Xing Pharmaceuticals reported
late-stage data for their experimental drug in Chinese patients
with paroxysmal supraventricular tachycardia (PSVT)
    ** PSVT is a condition which causes abnormal heart rhythm   
    ** Says the self-administered drug, etripamil nasal spray,
helped significantly greater proportion of patients return to
normal heart rhythm compared to placebo - MIST
    ** In 2021, MIST granted Ji Xing an exclusive license to
develop and commercialize etripamil, its lead experimental drug,
in patients with PSVT in Greater China
    ** Up to last close, stock down 12.6% YTD

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))